Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix

International Journal of Cancer

Volumn 132, Issue 8, 2013, Pages 1821-1830

  Formentin, Aurélie ^a   Archambault, Jacques ^b   Koushik, Anita ^c   Richardson, Harriet ^d   Brassard, Paul ^d   Franco, Eduardo L ^d   Coutlée, Francois ^a,d,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e NOTRE DAME HOSPITAL   (Canada)

Author keywords

anogenital cancer; cervical cancer; cervical dysplasia; HPV; viral polymorphism

Indexed keywords

PROTEIN E6; PROTEIN E7;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANADA; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; E6 GENE; E7 GENE; ETHNICITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN TISSUE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PRIORITY JOURNAL; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS GENOME;

ADULT; BASE SEQUENCE; CASE-CONTROL STUDIES; COHORT STUDIES; DNA PRIMERS; FEMALE; GENES, VIRAL; HUMANS; MALE; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 84873999392     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27874     Document Type: Article

References (48)

1. Ferenczy A, Franco EL,. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002; 3: 11-16.
2. Wang SS, Hildesheim A,. Viral and host factors in human papillomavirus persistence and progression. J NatlCancer Inst Monogr 2003; 35-40.
3. Chen Z, Terai M, Fu L, et al. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol 2005; 79: 7014-23.
4. Bernard HU, Calleja-Macias IE, Dunn ST,. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int J Cancer 2006; 118: 1071-76.
5. Giannoudis A, Herrington CS,. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 2001; 193: 295-302.
6. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475-87.
7. Castle PE, Schiffman M, Wheeler CM, et al. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010; 19: 1675-81.
8. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
9. Coutlée F, Ratnam S, Ramanakumar AV, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011; 83: 1034-41.
10. Aho J, Hankins C, Tremblay C, et al. Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis 2004; 190: 46-52.
11. Tran-Thanh D, Provencher D, Koushik A, et al. Herpes simplex virus type II (HSV-2) is not a cofactor to human papillomavirus in cancer of the uterine cervix. Am J Obstet Gyn 2003; 188: 129-34.
12. Koushik A, Ghosh A, Duarte-Franco E, et al. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Det Prev 2005; 29: 307-16.
13. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific HPV infections in female university students. Cancer Epidemiol Biomarkers Prev 2003; 12: 485-90.
14. Hamlin Douglas LK, Coutlee F, Roger M, et al. Determinants of human papillomavirus infection among Inuit women of northern Quebec, Canada. Sex Transm Dis 2010; 37: 377-81.
15. Hamlin Douglas LK, Coutlee F, Roger M, et al. Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev 2008; 17: 3141-49.
16. Coutlee F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human papillomavirus DNA in anogenital samples with PGMY primers and the LINEAR ARRAY HPV genotyping test. J Clin Microbiol 2006; 44: 1998-2006.
17. Coutlee F, Rouleau D, Ghattas G, et al. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol 2007; 45: 3821-23.
18. Aho J, Hankins C, Tremblay C, et al. Molecular analysis of human papillomavirus type 52 isolates detected in the genital tract of human immunodeficiency virus-seropositive and -seronegative women. J Infect Dis 2003; 188: 1517-27.
19. Thompson JD, Higgins DG, Gibson TJ, CLUSTAL W,: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22: 4673-80.
20. Shimoda K, Lorincz AT, Temple GF, et al. Human papillomavirus type 52: a new virus associated with cervical neoplasia. J Gen Virol 1988; 69: 2925-28.
21. Egawa K, Delius H, Matsukura T, et al. Two novel types of human papillomavirus, HPV 63 and HPV 65: comparisons of their clinical and histological features and DNA sequences to other HPV types. Virol 1993; 194: 789-99.
22. Calleja-Macias IE, Villa LL, Prado JC, et al. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol 2005; 79: 13630-40.
23. Chen Z, Schiffman M, Herrero R, et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011; 6: e20183.
24. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucl Acids Res 1998; 26: 362-67.
25. Chang YJ, Chen HC, Lee BH, et al. Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia. Int J Cancer 2011; 129: 965-73.
26. Gagnon S, Hankins C, Pourreaux K, et al. Polymorphism of the capsid L1 gene is not a determinant of persistence of HPV-52 infection in HIV-seropositive women. Can J Inf Dis 2006; 17: 29A.
27. Stewart AC, Eriksson AM, Manos MM, et al. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol 1996; 70: 3127-36.
28. Xin CY, Matsumoto K, Yoshikawa H, et al. Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett 2001; 170: 19-24.
29. Raiol T, Wyant PS, de Amorim RM, et al. Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, -52, and -58 in central Brazil. J Med Virol 2009; 81: 685-92.
30. Ding T, Wang X, Ye F, et al. Distribution of human papillomavirus 58 and 52 E6/E7 variants in cervical neoplasia in Chinese women. Gynecol Oncol 2010; 119: 436-43.
31. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010; 70: 3159-69.
32. Chan PK, Lam CW, Cheung TH, et al. Human papillomavirus type 16 intratypic variant infection and risk for cervical neoplasia in southern China. J Inf Dis 2002; 186: 696-700.
33. Gagnon S, Hankins C, Tremblay C, et al. Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women. J Infect Dis 2004; 190: 1575-85.
34. Grodzki M, Besson G, Clavel C, et al. Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev 2006; 15: 820-22.
35. Nindl I,. HPV variants and risk of cervical cancer. Papillomavirus Report 2002; 13: 1-6.
36. van Duin M, Snijders PJF, Vossen MTM, et al. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 2000; 81: 317-25.
37. Calleja-Macias IE, Kalantari M, Huh J, et al. Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. Virol 2004; 319: 315-23.
38. Xi LF, Kiviat NB, Hildesheim A, et al. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst 2006; 98: 1045-52.
39. Hildesheim A, Schiffman M, Bromley C, et al. Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001; 93: 315-18.
40. Burk RD, Terai M, Gravitt PE, et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res 2003; 63: 7215-20.
41. Lee K, Magalhaes I, Clavel C, et al. Human papillomavirus 16 E6, L1, L2 and E2 gene variants in cervical lesion progression. Virus Res 2008; 131: 106-10.
42. Khouadri S, Villa LL, Gagnon S, et al. Human papillomavirus type 33 polymorphism and high-grade lesions of the uterine cervix. J Inf Dis 2006; 194: 886-94.
43. Desaintes C, Demeret C,. Control of papillomavirus DNA replication and transcription. Sem Cancer Biol 1996; 7: 339-47.
44. Watts KJ, Thompson CH, Cossart YE, et al. Variable oncogene promoter activity of human papillomavirus type 16 cervical cancer isolates from Australia. J Clin Microbiol 2001; 39: 2009-14.
45. Hubert WG,. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle. J Virol 2005; 79: 5914-22.
46. Chong T, Apt D, Gloss B, et al. The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. J Virol 1991; 65: 5933-43.
47. O'Connor M, Bernard HU., Oct-1 activates the epithelial-specific enhancer of human papillomavirus type 16 via a synergistic interaction with NFI at a conserved composite regulatory element. Virol 1995; 207: 77-88.
48. Kyo S, Klumpp DJ, Inoue M, et al. Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells. J Gen Virol 1997; 78: 401-11.